About one-third of new drugs introduced in the U.S. from 2005 to 2012 were approved by government regulators on the basis of a single large clinical trial, according to a new study.. The wide variation in evidence behind new drugs approved by the U.S. Food and Drug Administration should be more clearly communicated to the public, according to the authors of the study, which was published Tuesday in the Journal of the American Medical Association.